Cipla Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Cipla Ltd. authored by Asit C Mehta Investment Interrmediates and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 4
Author: Asit C Mehta Investment Interrmediates

Keep track of all breaking news and updates on Cipla Ltd. from all sources in a single place.

Load latest

Cipla Ltd.

20 Jan 2025

1415.25

-5.38%

Company Update

CIPLA LTD. - 500087 - USFDA Inspection At Manufacturing Facility Of Medispray In Kundaim, Goa, India

BSE India

USFDA inspection at manufacturing facility of Medispray Laboratories Private Limited in Kundaim, Goa, India

pdf

Cipla Ltd.

17 Jan 2025

1415.25

-5.38%

Company Update

CIPLA LTD. - 500087 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) …

BSE India

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

pdf

Cipla Ltd.

17 Jan 2025

1415.25

-5.38%

Empowering health, Enriching Lives

Accumulate: Cipla Ltd.

Asit C Mehta Investment Interrmediates

Cipla's "Future Fit" strategy outlines ambitious growth objectives, including becoming India’s 2nd largest pharmaceutical company, leading South Africa’s prescription and OTC markets, ranking 2nd in U.S. respiratory generics, and doubling international revenue.

Number of FII/FPI investors decreased from 1132 to 1077 in Dec 2024 qtr

Cipla Ltd.

15 Jan 2025

1415.25

-5.38%

Company Update

CIPLA LTD. - 500087 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018

pdf

Cipla Ltd.

14 Jan 2025

1415.25

-5.38%

Company Update

CIPLA LTD. - 500087 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) …

BSE India

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

pdf

Cipla Ltd.

08 Jan 2025

1415.25

-5.38%

Company Update

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 28th January, 2025.

pdf

Cipla Ltd.

06 Jan 2025

1415.25

-5.38%

Board Meeting

CIPLA LTD. - 500087 - Board Meeting Intimation for Meeting Of The Board Of Directors Of …

BSE India

CIPLA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 ,inter alia, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 31st December, 2024.

pdf

Cipla Ltd.

06 Jan 2025

1415.25

-5.38%

Cipla launches CipAir mobile app for first-line asthma screening in India

Business Standard

The app aims to assess users' likelihood for asthma, thereby enabling timely intervention and management

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

20 Dec 2024

1415.25

-5.38%

GST authority imposes Rs 1 cr fine on Cipla for inadmissible credit claim

Business Standard

Pharma major Cipla Ltd on Friday said a fine of over Rs 1 crore has been imposed on the company by GST authority for alleged inadmissible credit claim. The company has received an order dated December 18, 2024 passed by the GST authority, imposing a penalty of Rs 1,11,94,324 under applicable provisions of the Central Goods and Services Tax Act, 2017, Cipla said in a regulatory filing. "The order has been passed by GST Authority on the contention that the company has availed inadmissible TRAN-1 credit. The GST Authority has ordered for recovery of the same along with applicable interest and penalty," it added. Cipa said based on assessment of facts and prevailing law, it is "of the view that the penalty levied is arbitrary and unjustified". "The company will file necessary appeals with the appellate authority in this regard. There is no material impact on the company's financials or operations due to the said order," it added.